Chronic Hepatitis News

Results from an estimation model revealed that Australia will marginally miss both its local targets and the WHO’s global targets for eliminating chronic hepatitis B.

Results from a systematic review and meta-analysis revealed 13 risk factors for intrahepatic and extrahepatic cholangiocarcinoma, the most significant of which included biliary cysts and stones, cirrhosis, hepatitis B and hepatitis C.

The rate of newly diagnosed acute and chronic hepatitis B virus infections in women of childbearing age has significantly increased in some Appalachian states, despite overall national rates that have declined or remained stable.

By 2019, hepatitis C-seronegative patients who underwent kidney transplantation mostly received HCV-viremic donor organs, which demonstrated the same level of function as uninfected kidneys over the course of 1-year follow-up.

Resistance-guided direct-acting antiviral retreatment resulted in nearly 90% sustained virologic response rates among patients with hepatitis C who developed resistance-associated substitutions after failing treatment with NS5A inhibitors.

Researchers discovered that an elevated fatty liver index was an independent risk factor for all-cause mortality in patients coinfected with hepatitis C and HIV, regardless of liver fibrosis or sustained virologic response to hepatitis therapy.

The FDA approved changes to the labeling of direct-acting antivirals Sovaldi and Harvoni to include information on dosage and administration in pediatric patients with hepatitis C aged 3 years to younger than 12 years.

Janssen Pharmaceuticals initiated patient dosing in a phase 2b study of different regimens for the treatment of chronic hepatitis B including combinations of JNJ-3989, JNJ-6379 and nucleos(t)ide analog therapy, according to a press release from study collaborator, Arrowhead Pharmaceuticals.

The FDA has received reports that the use of Mavyret, Zepatier or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver disease has resulted in rare cases of liver injury or liver failure, according to a drug safety communication.

Results from two independent cohorts revealed that patients who had negative test results for both hepatitis B DNA and hepatitis B RNA at the end of nucelos(t)ide analogue therapy were more likely to have continued response for 4 years or more.